Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Apple Turns 50: From Garage Startup to AI Crossroads 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
GAITHERSBURG, Md., Dec. 06, 2016 -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that its abstract related to the development of an assay to detect low frequency antigen-specific T cells in HepTcell trial participants was accepted for presentation at the BSI/NVVI Congress 2016 taking place December 6 - 9, 2016 in Liverpool, U.K. HepTcell is Altimmune’s first-in-class T cell-activating immunotherapeutic in development for the treatment of chronic hepatitis B (CHB). A Phase 1 trial is currently underway.
The BSI/NVVI Congress 2016 is a joint collaboration between the British Society for Immunology (BSI) and the Dutch Society for Immunology (NVVI), two of Europe’s most established immunology organizations, to bring together the latest in cutting-edge immunology research.
The poster, entitled, “Development of a cultured ELISpot assay to detect low frequency antigen-specific T cells in PBMC from HBV therapeutic vaccine trial participants," will be presented by V. Motskin on Thursday, December 8, 2016 from 5:30 – 7:30 PM GMT.
About Altimmune
Altimmune is a clinical stage immunotherapeutic company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines. Using these technologies, Altimmune has developed three novel clinical stage product candidates that potentially represent an entirely new approach to harnessing the immune system.
The Company’s most advanced product candidate, NasoVAX, is a Phase 2-ready intranasally-delivered recombinant influenza vaccine offering broad and rapid protection with potential for significant advantages over traditional flu vaccines. The second most advanced product candidate, HepTcell, is being tested as an immunotherapy for patients chronically infected with hepatitis B and has the potential to provide a functional cure. With the support of the U.S. Biomedical Advanced Research and Development Authority, or BARDA, the Company is developing a third product candidate, NasoShield, a first-in-class anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. The Company intends to leverage the RespirVec and Densigen platforms to develop additional product candidates for a variety of indications.
Contacts: Bill Enright President and CEO Altimmune, Inc. Phone: 240-654-1450 Email: [email protected] Investor Relations Stephanie Carrington ICR, Inc. Phone: 646-277-1282 Email: [email protected]
